Cargando…
New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Spinal muscular atrophy (SMA) is a congenital neuromuscular disorder characterized by motor neuron loss, resulting in progressive weakness. SMA is notable in the health care community because it accounts for the most common cause of infant death resulting from a genetic defect. SMA is caused by low...
Autor principal: | Chen, Tai-Heng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246502/ https://www.ncbi.nlm.nih.gov/pubmed/32392694 http://dx.doi.org/10.3390/ijms21093297 |
Ejemplares similares
-
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
por: d’Ydewalle, Constantin, et al.
Publicado: (2015) -
New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023) -
Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020) -
Where Do We Stand?
Publicado: (1891) -
Gene therapy for arthritis – where do we stand?
por: Chernajovsky, Yuti
Publicado: (2005)